Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 5,538 shares at $60.71 ($336K) on 2026-06-15, disclosed to the SEC on 2026-06-17.
Scheduled sale ($336k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |
| NKTR | SELL | 2026-01-22 | $138K | — | Filing → |